The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for System Biosciences sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.

Smarter leaders trust GlobalData


Data Insights System Biosciences LLC, United States Revenue

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

System Biosciences LLC (SBI) is a biotechnology company that develops technology tools for molecular and cell biology research. It offers exosome research, CRISPR/Cas9 systems, lentivirus production, gene expression systems, imaging and reporter Vectors and miRNA & lncRNA research tools. SBI’s life science research products include Lenti-miR precursor vectors, miRZip knockdown vectors, Lenti-miR libraries, signaling pathway reporters, cyto-tracers, minicircle technology, virus concentration kits and titering, Cas9 and gRNA delivery, HR targeting vectors, exosome detection products and exosome biomarker discovery products. SBI’s products find application in biomarker discovery, cancer research, exosome isolation, exosome characterization, exosome engineering, gene delivery, gene editing, inducible gene expression and in vivo imaging, among others. The company operates through network of distributors in Africa, Australia, Austria, Germany, Hong Kong, Hungary, India, Ireland, Israel, and others. SBI is headquartered in Palo Alto, California, the US.

The key metrics of System Biosciences related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:

As System Biosciences is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as System Biosciences.

For a detailed understanding of the performance of System Biosciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.